<DOC>
	<DOCNO>NCT00423865</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Everolimus may stop growth tumor cell block enzymes need cell growth . Everolimus may also help cisplatin work well make tumor cell sensitive drug . Giving cisplatin together everolimus may kill tumor cell . PURPOSE : This phase I trial study side effect best dose everolimus give together cisplatin treat patient advance solid tumor recurrent metastatic solid tumor .</brief_summary>
	<brief_title>Cisplatin Everolimus Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine recommend phase II dose everolimus administer low-dose cisplatin patient advance solid tumor . Secondary - Determine safety tolerability regimen patient . - Describe pharmacokinetics regimen patient advance solid tumor . - Assess effect regimen p53 p21 immunohistochemistry assay pre- post-treatment tumor biopsy patient recurrent metastatic solid tumor . OUTLINE : This dose-escalation study everolimus ( part A ) follow biological marker study ( part B ) . - Part A ( closed accrual 1/2009 ) : Patients receive cisplatin* IV 30 minute day 1 , 8 , 15 oral everolimus* daily day 1-21 . Treatment repeat every 28 day 1 year absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos everolimus maximum tolerate dose ( MTD ) determine . The MTD define dose proceed 2 6 patient experience dose-limiting toxicity ( DLT ) course 1 . The recommended phase II dose define dose 1 6 patient experience DLT course 1 . Blood drawn periodically day 1 8 course 1 pharmacokinetic study . - NOTE : *Patients complete 5 course treatment maintain stable disease well may continue treatment everolimus alone combination cisplatin - Part B : Patients undergo biopsy primary tumor , metastatic deposit , involve lymph node . No 14 day later , patient receive everolimus recommend phase II dose cisplatin part A . Patients undergo another tumor biopsy day 15 course 1 , receive chemotherapy . The pre- post-therapy tissue examine immunochemistry analyze p53 p21 expression . PROJECTED ACCRUAL : A total 30 people accrue study .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Advanced solid tumor ( part A ) Confirmation core biopsy fineneedle aspiration allow Solid tumor ( part B ) Recurrent metastatic disease Easily accessible biopsy Measurable disease No uncontrolled brain leptomeningeal metastases No requirement glucocorticoid PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin &gt; 10 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( &lt; 5 time ULN liver metastasis present ) Creatinine normal OR creatinine clearance ≥ 55 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month completion study therapy No HIV positivity No peripheral neuropathy ≥ grade 2 No hypertriglyceridemia ≥ grade 2 No impaired gastrointestinal function gastrointestinal disease may alter absorption everolimus , include follow : Ulcerative disease Uncontrolled nausea Vomiting Diarrhea Malabsorption syndrome Small bowel resection No concurrent severe and/or uncontrolled medical disease would compromise study participation , include follow : Uncontrolled diabetes Unstable angina New York Heart Association class III IV congestive heart failure PRIOR CONCURRENT THERAPY : No 3 prior cytotoxic chemotherapy regimens recurrent metastatic disease At least 4 week since prior major surgery recover At least 4 week since prior radiation therapy recover At least 4 week since prior systemic anticancer therapy recover At least 4 week since prior concurrent investigational drug No prior everolimus agent specifically target mTOR No prior radiation therapy &gt; 25 % bone marrow No prior radiation therapy whole pelvis and/or brain No concurrent chronic steroid treatment ( &gt; 5 mg/day prednisone ) Concurrent lowdose steroid replacement regimen ( ≤ 5 mg/day prednisone ) allow No concurrent immunosuppressive agent No concurrent anticancer agents No concurrent agent know strong inhibitor inducer isoenzyme CYP3A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>CISPLATIN</keyword>
	<keyword>RAD001 ( EVEROLIMUS )</keyword>
	<keyword>06-129</keyword>
</DOC>